Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding round, welcoming on board new venture capital business Tenmile as
Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a
Carina Biotech has entered a license agreement with Bayerische Patentallianz (BayPAT) to the CXCR6-transduced CAR-T cell technology developed at the University Hospital of Ludwig-Maximillian University of Munich (LMU). The agreement
We are very pleased to welcome to our corporate team Jade Foeng, researcher & PhD student in Professor Shaun McColl's lab at University of Adelaide. Jade, a researcher with Carina for 3+
Carina Biotech's four-member Medical Advisory Board will advise us as we prepare to take our LGR5-targeted CAR-T cell for advanced colorectal cancer into the clinic over the next 12-18 months.
Dr Deborah Rathjen After completing its first (and second) commercial deals in the middle of last year, Carina is now rapidly transitioning from CAR-T discovery company to an emerging clinical
Carina Biotech and biopharmaceutical company Biosceptre are pleased to announce they have signed an agreement that will see the advancement of a promising cancer immunotherapy. Biosceptre, developing targeted therapeutics and immune-oncology products,
Carina Biotech was one of six Adelaide start-ups to share in more than $2.75 million through the State Government's Research Commercialisation and Startup Fund (RCSF). Minister for Innovation and Skills,
Jade Foeng, research scientist and PhD student from the McColl lab at the University of Adelaide, has finished up a two-month stint at Seattle Children's Research Institute Seattle Children's in the
